Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
No Placebo
Drugs
Locations
Clinical Specialty
81-100 of 2,251 trials

Pembrolizumab for Children with Advanced Melanoma and Solid Tumors

We are studying the safety and effectiveness of pembrolizumab in children with advanced melanoma or certain relapsed solid tumors and lymphoma. This trial aims to understand how well this treatment works and its potential side effects.

Advanced Melanoma and Related CancersSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncologyPediatrics

Brexucabtagene Autoleucel for Rare B-cell Malignancies

We are studying a new treatment for adults with relapsed or refractory Richter Transformation of B-cell malignancies. The goal is to see if it improves response rates and overall survival compared to existing options.

Relapsed/Refractory Richter Transformation1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Colorectal Cancer: UNICORN Study on Targeted Preoperative Treatments

We are studying short-course targeted treatments for patients with resectable colorectal cancer to see if they improve treatment response and quality of life. This trial aims to understand the safety and effectiveness of these treatments before surgery.

Colorectal Adenocarcinoma1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Preventing Second Cancers: Dostarlimab Study

We are studying whether dostarlimab can help prevent second primary cancers in patients who have been cured of their first cancer. This trial will also look at the safety of the treatment.

Cancer Survivor at Risk for Second Cancer≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncology

Multiple Sclerosis: Ozanimod vs. Fingolimod

We are studying whether the new medication ozanimod is more effective and safe than fingolimod for children and adolescents with relapsing remitting multiple sclerosis. This trial will also assess how the body handles ozanimod.

Relapsing-Remitting Multiple SclerosisConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurology

Acute Myeloid Leukemia: Oral-Azacitidine with Gilteritinib

We are studying a new combination treatment for adults with relapsed or refractory FLT3-mutated acute myeloid leukemia. The goal is to see if this approach improves remission rates and safety compared to current options.

Acute Myeloid Leukaemia>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

COVID-19 Treatment: Antiviral Therapy for Immunocompromised Patients

We are studying a combination of antiviral medications to see if it helps immunocompromised patients recover from COVID-19 more effectively. The goal is to improve viral clearance and reduce symptoms compared to standard treatments.

Covid-193-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Cognitive Deficits in Multiple Sclerosis: MODAFIMS Study

We are studying the effects of modafinil on cognitive deficits in people with Multiple Sclerosis. The trial aims to identify brain features that may predict treatment response and assess changes in cognitive function and quality of life.

Multiple Sclerosis6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesNeurology

Breast Cancer: Elacestrant vs. Standard Therapy

We are studying whether elacestrant can help women with ER+/HER2- breast cancer who have signs of relapse delay cancer spread compared to standard treatments. The trial also looks at safety and how patients feel about the treatment.

Breast Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesOncology

ALK-Positive Anaplastic Large Cell Lymphoma: Vinblastine Treatment

We are studying whether Vinblastine can effectively treat children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma. The goal is to see if it can cure at least 75% of these patients.

ALK-positive Anaplastic Large Cell Lymphoma>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesOncologyPediatrics

Atypical Teratoid/Rhabdoid Tumors: High-Dose Chemotherapy vs. Radiotherapy

We are studying whether high-dose chemotherapy is as effective as radiotherapy for young children with ATRT. This trial aims to improve treatment options and understand the long-term effects on health and quality of life.

Atypical Teratoid/Rhabdoid Tumors (ATRT)>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncologyPediatrics

Hypertension in Chronic Kidney Disease: Diuretic Treatment Study

We are investigating if a new diuretic-based treatment helps people with moderate to severe chronic kidney disease and uncontrolled hypertension. The goal is to see if it can reduce serious health issues like kidney failure and heart problems.

Chronic Kidney DiseaseUncontrolled Hypertension>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCardiologyNephrology

HER2-positive Breast Cancer: Trastuzumab Deruxtecan Study

We are comparing a new treatment with standard therapy for patients with HER2-positive breast cancer. The goal is to see which approach leads to better outcomes and to understand the effects on quality of life.

HER2 Positive Breast Cancer3-6 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Triple-Negative Breast Cancer: PLX038 Treatment Study

We are studying the effects of PLX038 in patients with locally advanced or metastatic triple-negative breast cancer. The goal is to see how well it works and to understand its safety and tolerability.

Advanced Triple-Negative Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Multiple Myeloma: Iberdomide vs. Lenalidomide Maintenance Therapy

We are comparing two treatments for newly diagnosed multiple myeloma patients after stem cell transplant to see which one may help keep the disease from worsening. This study will also look at safety and quality of life for participants.

Newly Diagnosed Multiple Myeloma>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Prostate Cancer: Surgery with Darolutamide

We are studying whether adding darolutamide before and after surgery helps improve survival and quality of life for patients with high-risk or locally advanced prostate cancer.

Prostate Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncologyUrology

Pneumococcal Vaccine Response in Lymph Nodes

We are studying how the immune system reacts to the pneumococcal vaccine by analyzing lymph nodes. This research may help us understand the timing and types of immune cells involved in the vaccine response.

Healthy VolunteersEfficacy phase (II)No PlaceboInvestigational MedicinesAllergologyInfectious Diseases

Breast Cancer: Ribociclib with Hormone Therapy and Radiotherapy

We are studying the safety and effectiveness of Ribociclib combined with hormone therapy and radiotherapy for elderly patients with hormone-positive, HER2-negative breast cancer. This trial is for those newly diagnosed who are not ready for surgery.

Breast Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology

Osimertinib (TAGRISSO) Continuation Study

We are providing ongoing treatment with osimertinib for patients who have benefited from it in a previous study. The goal is to monitor safety and tolerability as they continue their treatment.

Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Corticosteroid Treatment for Acute Myocarditis

We are studying whether intravenous corticosteroids can improve heart function in patients with acute myocarditis and mildly reduced heart performance. This trial compares corticosteroid therapy to standard treatment options.

Acute Myocarditis>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine